Kexing Pharmaceutical (SHA: 688136), based in China, has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study targeting childhood growth hormone deficiency.
The clinical trial will investigate a Category I innovative product candidate, an Fc fusion protein designed as a long-acting growth hormone. This molecule utilizes DNA recombination technology to enhance product safety and improve patient adherence to treatment by linking the human growth hormone (hGH) gene with the IgG4 subtype Fc segment gene for expression.- Flcube.com
